secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001178913-26-002393
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split
--------------------------------------------------------------------------------

- Authorized shares increased from 9M to 59M via Memorandum Amendment effective May 5, 2026.
- Equity incentive plan evergreen provision raised from 5% of outstanding to pool of 10% fully diluted shares annually.
- Reverse stock split at 1-for-10 approved; can be reduced to maintain Nasdaq minimum public float.
- All three proposals passed with ~61% of votes in favor at reconvened meeting with 40.2% quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/0001178913-26-002393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/zk2635202.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer